Eli Lilly & Co. (LLY)

112.72
0.59 0.52
NYSE : Health Technology
Prev Close 113.31
Open 112.88
Day Low/High 112.08 / 113.36
52 Wk Low/High 73.69 / 116.61
Volume 1.36M
Avg Volume 4.08M
Exchange NYSE
Shares Outstanding 1.07B
Market Cap 121.99B
EPS -0.20
P/E Ratio N/A
Div & Yield 2.25 (1.99%)

Latest News

New Data Showcasing Lilly's Growing Commitment In Rheumatology To Be Featured At The ACR/ARHP Annual Meeting

New Data Showcasing Lilly's Growing Commitment In Rheumatology To Be Featured At The ACR/ARHP Annual Meeting

- Forty-one abstracts supporting Taltz® and Olumiant® reveal new data including findings in ankylosing spondylitis (radiographic axial spondyloarthritis), psoriatic arthritis, systemic lupus erythematosus and rheumatoid arthritis -

Lilly And Metastatic Breast Cancer Advocates Launch Thriver Movement To Elevate Understanding Of The Daily Impact Of The Disease, Encourage Public To Do More For MBC

Lilly And Metastatic Breast Cancer Advocates Launch Thriver Movement To Elevate Understanding Of The Daily Impact Of The Disease, Encourage Public To Do More For MBC

- National survey uncovers majority of people living with MBC say the daily stress and anxiety they experience associated with the disease can impact everything from relationships to careers, with many experiencing mental health conditions

New Analysis Estimates The Positive Impact Of Jardiance® On Life Expectancy In Adults With Type 2 Diabetes And Established Cardiovascular Disease

New Analysis Estimates The Positive Impact Of Jardiance® On Life Expectancy In Adults With Type 2 Diabetes And Established Cardiovascular Disease

- Survival estimates from the EMPA-REG OUTCOME® trial data demonstrate potential long-term benefit of Jardiance (empagliflozin) on life expectancy of adults with type 2 diabetes and cardiovascular disease

Lilly To Present New Data From Oncology Portfolio At ESMO 2018 Congress, Showcasing Patient-Centric Advances In Cancer Care

Lilly To Present New Data From Oncology Portfolio At ESMO 2018 Congress, Showcasing Patient-Centric Advances In Cancer Care

Data from abemaciclib, pemetrexed and ramucirumab late-stage clinical development programs in multiple difficult-to-treat tumor types

Ford May Look Like a Value but It's Currently Dead Money

Ford May Look Like a Value but It's Currently Dead Money

There are concerns that interest rates may start to impact new car sales.

Running Hot: Cramer's 'Mad Money' Recap (Friday 10/5/18)

Running Hot: Cramer's 'Mad Money' Recap (Friday 10/5/18)

Jim Cramer says it'll be hard for stocks to stabilize until the Fed's stance softens. He's got your game plan for next week.

Dow, S&P 500 and Nasdaq End Sharply Lower as Interest Rates Surge

Dow, S&P 500 and Nasdaq End Sharply Lower as Interest Rates Surge

The Dow Jones Industrial Average and other major indexes all end sharply lower U.S. Treasury yields surge.

Constellation Brands Is a Bright Star on a Down Day

Constellation Brands Is a Bright Star on a Down Day

With STZ's earnings beat and the potential of the CGC investment, investors are willing to pay a premium.

Boehringer Ingelheim And Lilly Present Full Results Of Tradjenta®'s CARMELINA® Cardiovascular Outcome Trial

Boehringer Ingelheim And Lilly Present Full Results Of Tradjenta®'s CARMELINA® Cardiovascular Outcome Trial

- Tradjenta® (linagliptin) demonstrated similar long-term cardiovascular safety compared with placebo in adults with type 2 diabetes

Major Shifts in Investment Themes, Higher Interest Rates Shake up the Market

Major Shifts in Investment Themes, Higher Interest Rates Shake up the Market

This is a market driven by macro matters and is not as favorable to stock pickers right now.

Boehringer Ingelheim And Lilly Present Full Results From EASE Phase III Program For Empagliflozin As Adjunct To Insulin In Type 1 Diabetes

Boehringer Ingelheim And Lilly Present Full Results From EASE Phase III Program For Empagliflozin As Adjunct To Insulin In Type 1 Diabetes

- All investigated doses met the primary efficacy endpoint defined as a change from baseline in A1C versus placebo after 26 weeks of treatment

Lilly's Investigational Dual GIP And GLP-1 Receptor Agonist Shows Significant Reduction In HbA1c And Body Weight In People With Type 2 Diabetes

Lilly's Investigational Dual GIP And GLP-1 Receptor Agonist Shows Significant Reduction In HbA1c And Body Weight In People With Type 2 Diabetes

INDIANAPOLIS, Oct. 4, 2018 /PRNewswire/ -- Results from a phase 2b clinical trial of Eli Lilly and Company's (NYSE: LLY) dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA, LY3298176) showed strong and clinically meaningful blood sugar reduction and weight...

Lilly Confirms Date And Conference Call For Third-Quarter 2018 Financial Results Announcement

Lilly Confirms Date And Conference Call For Third-Quarter 2018 Financial Results Announcement

INDIANAPOLIS, Oct. 3, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2018 on Tuesday, November 6, 2018.

Intel Regains Its Leadership Position in the Semiconductor Sector

Intel Regains Its Leadership Position in the Semiconductor Sector

The stock still needs to do more work to be convincing.

Results From Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint In People With Type 1 And Type 2 Diabetes

Results From Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint In People With Type 1 And Type 2 Diabetes

Both studies also showed greater reductions in glucose excursions after mealtime

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Tesla and More Mark End of Quarter; FDA OKs Lilly's Migraine Drug -- ICYMI

Tesla and More Mark End of Quarter; FDA OKs Lilly's Migraine Drug -- ICYMI

Here's what you need to know now for Sept. 28.

Dow Ends Up for Day, Month and Quarter; Tesla Tumbles on Musk Fraud Charges

Dow Ends Up for Day, Month and Quarter; Tesla Tumbles on Musk Fraud Charges

Stocks ended near breakeven on the last trading day of the third quarter.

Eli Lilly's FDA-Approved Migraine Drug is Welcomed by the 38 Million Sufferers

Eli Lilly's FDA-Approved Migraine Drug is Welcomed by the 38 Million Sufferers

With 38 million Americans suffering from migraines, the FDA's approval of Eli Lilly's preventative migraine drug Emgality can help them get their lives back. We spoke with Christi Shaw, president, Lilly Bio-Medicines for all the details.

Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval For The Preventive Treatment Of Migraine In Adults

Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval For The Preventive Treatment Of Migraine In Adults

INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.

Https://www.lilly.com/

Https://www.lilly.com/

Chugai Pharmaceutical Co., Ltd.

Alphabet Before Congress, Fed Decision Make for an Interesting Day

Alphabet Before Congress, Fed Decision Make for an Interesting Day

Traders are likely remembering what Facebook stock did when Mark Zuckerberg testified before Congress.

A Brief Bird's Eye View of Fresh IPO Elanco Animal Health

A Brief Bird's Eye View of Fresh IPO Elanco Animal Health

The limited technical data for the recent Eli Lilly spinoff indicate buyers came in early and appear to be holding.

The Bears Have it Backwards: Cramer's 'Mad Money' Recap (Monday 9/24/18)

The Bears Have it Backwards: Cramer's 'Mad Money' Recap (Monday 9/24/18)

Jim Cramer says traders hate hearing about long-term investing because they want instant payoffs.

Newly Public Elanco Seeks to Innovate With Offering Proceeds

Newly Public Elanco Seeks to Innovate With Offering Proceeds

See what this little known veteran of a company has in store in the animal health industry.

Elanco Animal Health Incorporated Announces IPO Closing

Elanco Animal Health Incorporated Announces IPO Closing

Elanco Animal Health Incorporated today announced the closing of its previously announced initial public offering ("IPO") of 62.

Elanco Announces Full Exercise Of Additional Stock, Sets Date For Q3 Earnings

Elanco Announces Full Exercise Of Additional Stock, Sets Date For Q3 Earnings

Elanco Animal Health Incorporated (NYSE:ELAN) announced the underwriters of its initial public offering (IPO) have fully exercised their option to purchase an additional 9.

Lilly Receives Positive CHMP Opinion For Emgality™ (galcanezumab) For The Prophylaxis Of Migraine In Adults

Lilly Receives Positive CHMP Opinion For Emgality™ (galcanezumab) For The Prophylaxis Of Migraine In Adults

INDIANAPOLIS, Sept. 21, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality ™ (galcanezumab) for...

TheStreet Quant Rating: C+ (Hold)